drugset

drugset / Trial / NCT00708214

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

NCT00708214 ↗

Phase 2 Completed 28 enrolled Boehringer Ingelheim

Non-randomizedOpen-labelTreatment

Summary

Progression-free rate after 16 weeks of BIBW 2992 administration in association with letrozole

Timeline

Start: 2007-01
Primary completion: 2010-02
Completion: —

Publications

Gunzer K, Joly F, Ferrero JM, Gligorov J, de Mont-Serrat H, Uttenreuther-Fischer M, Pelling K, Wind S, Bousquet G, Misset JL. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. Springerplus. 2016 Jan 19;5:45. doi: 10.1186/s40064-015-1601-7. eCollection 2016.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Afatinib	Small molecule	30 mg	Oral
Subject	Afatinib	Small molecule	40 mg	Oral
Subject	Afatinib	Small molecule	50 mg	Oral
Background	Letrozole	Other / unclassified	2.5 mg	—

Indications